Cognitive bias evaluation on the choice of treatment in common retinal disorders among retina specialists in 2023

CONCLUSION: The findings regarding the first and second line choices for the mentioned ocular disorders were found to agree with the findings of published literature currently used in practice, with a tendency to prefer ranibizumab as first line therapy for neovascular disorders and aflibercept as first line therapy for macular edema. In addition, there were no differences between choices for first and second line therapy for patients vs. ophthalmologists.PMID:38603895 | DOI:10.1016/j.jfo.2024.104177
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Authors: Source Type: research